NCT00001566View on ClinicalTrials.gov

A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 31, 1996

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Ewing's SarcomaRhabdomyosarcoma
Interventions
BIOLOGICAL

therapeutic autologous dendritic cells

3 syringes containing 1 x 10\^6peptide pulsed dendritic cells

DRUG

indinavir sulfate

Oral dose, 350 mg/m\^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours.

PROCEDURE

peripheral blood stem cell transplantation

Harvested autologous T cells, minimum dose 1 x 10\^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00001566 - A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas | Biotech Hunter | Biotech Hunter